Table 3 Expression of phenotypic markers in 76 small bowel carcinomas: their distribution among clinical groups and prognostic value

From: Small bowel carcinomas in celiac or Crohn’s disease: distinctive histophenotypic, molecular and histogenetic patterns

 

Distribution among the clinical groups

Total

Survival analysis

 

Celiac disease carcinomas (n=26)

Crohn’s disease carcinomas (n=25)

Sporadic carcinomas (n=25)

 

Hazard ratio (95% confidence interval)

P-value

Cytokeratin 7

5 (19%)a

15 (60%)b

4 (16%)

24 (32%)

2.72 (1.18–6.29)

0.019

MUC5AC

5 (19%)

13 (52%)

5 (20%)

23 (30%)

2.54 (1.08–5.98)

0.032

CDX2

21 (81%)c

9 (36%)

17 (68%)

47 (62%)

0.28 (0.13–0.63)

0.002

MUC2

18 (69%)

12 (48%)

12 (48%)

42 (55%)

0.25 (0.12–0.53)

<0.001

Cytokeratin 20

13 (50%)

9 (36%)d

20 (80%)

42 (55%)

1.19 (0.57–2.50)

0.635

CD10

8 (31%)

3 (12%)

11 (44%)

22 (29%)

0.66 (0.30–1.65)

0.302

Intestinal phenotype

17 (65%)e

5 (20%)f

17 (68%)

39 (51%)

0.39 (0.18–0.81)g

0.012

  1. aP=0.004 vs Crohn’s disease-associated carcinomas.
  2. bP=0.003 vs sporadic carcinomas.
  3. cP=0.002 vs Crohn’s disease-associated carcinomas.
  4. dP=0.004 vs sporadic carcinomas.
  5. eP=0.002 vs Crohn’s disease-associated carcinomas.
  6. fP=0.001 vs sporadic carcinomas.
  7. gVs remaining 37 cases expressing gastro-pancreatobiliary markers.
Back to article page